ArticleERJ open research2019
Efficacy of two dosing schemes of a liquid containing ivy leaves dry extract EA 575
Article in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Ivy leaves extract EA 575 in the treatment of cough during acute respiratory tract infections: meta-analysis of double-blind, randomized, placebo-controlled trials.Scientific reports · 2022Pooled it
- Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review.European journal of clinical pharmacology · 2021Pooled it
- Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms.Journal of Korean medical science · 2026Trial
- Efficacy and safety of AtusinBMC pulmonary medicine · 2025Trial
- From Traditional Remedy to Evidence-Based Phytotherapeutic Agent:Plants (Basel, Switzerland) · 2026Review
- Efficacy and Safety of Ivy Leaf Dry Extract EA 575 in Cough Management: An Updated Review of Clinical Evidence.Planta medica · 2026Review
- A Review of the Properties of Clinically Evaluated Plant-Derived Agents in the Treatment of Respiratory Infections.Nutrients · 2026Review
- Reply to Cho, P.S.P. Comment on "Kardos et al. Efficacy and Safety of a Single Ivy Extract Versus Two Herbal Extract Combinations in Patients with Acute Bronchitis: A Multi-Center, Randomized, Open-Label Clinical Trial.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy of EA575 as an Antitussive and Mucoactive Agent in Preclinical In Vivo Models.Biomedicines · 2025Article
- Ivy Leaf Dry Extract EA 575Pharmaceutics · 2025Article
- Efficacy and Safety of a Single Ivy Extract Versus Two Herbal Extract Combinations in Patients with Acute Bronchitis: A Multi-Center, Randomized, Open-Label Clinical Trial.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Investigation into the Effectiveness of an Herbal Combination (AngocinAntibiotics (Basel, Switzerland) · 2024Article
- Well-Established and Traditional Use of Vegetal Extracts as an Approach to the "Deep Roots" of Cough.Children (Basel, Switzerland) · 2024Review
- Ivy Leaf Dry Extract EA 575International journal of molecular sciences · 2023Article
- Disease burden in a large cohort of asylum seekers and refugees in Germany.Journal of global health · 2021Article
- Assessment of the Efficacy and Safety of Ivy Leaf (Evidence-based complementary and alternative medicine : eCAM · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe results of a clinical trial published in 2016 showed the efficacy of ivy leaves dry extract EA 575
methodsThis randomised, placebo-controlled, multicentre, double-blind clinical trial was conducted to assess the efficacy and safety of a liquid containing EA 575 in the treatment of acute bronchitis. A total of 209 patients were treated with a liquid containing EA 575 as an active investigational medicinal product (verum) either two (7.5 mL) or three (5 mL) times a day or placebo in the respective dosing scheme for 1 week, with a total observational period of 2 weeks. The primary efficacy outcome was a change in Bronchitis Severity Score (BSS) of the pooled placebo and pooled verum groups between visits 1 and 5. Additional secondary parameters were assessed, including, for example, change in cough severity as assessed by a visual analogue scale (VAS) and the Verbal Category Descriptive (VCD) score.
resultsSuperiority of verum over placebo was during and at the end of treatment, as measured by BSS. No significant differences between the dosing schemes were observed. VCD scores and VAS measurements also showed the superiority of verum over placebo.
conclusionThe existing data on the clinical efficacy of EA 575 were confirmed. Furthermore, a new dosing scheme was shown to be noninferior to the currently used scheme while maintaining the safety and tolerability of the well-established cough liquid containing EA 575.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.